ALLMedicine™ Myoclonic Epilepsy Center
Research & Reviews 107 results
https://doi.org/10.1016/j.seizure.2022.05.005
Seizure Kılıç B, Serdaroğlu E et. al.
May 21st, 2022 - Valproic acid (VPA) is frequently used and effective in juvenile myoclonic epilepsy (JME). Recently, levetiracetam (LEV) has been suggested as a monotherapy in JME. This study aimed to evaluate antiseizure medication (ASM) use in patients with JME...
https://doi.org/10.1002/hbm.25873
Human Brain Mapping; Liu G, Zheng W et. al.
Apr 14th, 2022 - Neuroimaging studies have shown that juvenile myoclonic epilepsy (JME) is characterized by impaired brain networks. However, few studies have investigated the potential disruptions in rich-club organization-a core feature of the brain networks. Mo...
https://doi.org/10.1016/j.seizure.2022.03.002
Seizure Asadi-Pooya AA, Rostamihosseinkhani M et. al.
Mar 9th, 2022 - To investigate the seizure outcome in patients with juvenile myoclonic epilepsy (JME) and its associated factors. We also investigated the social outcome of these patients. This was a retrospective study. All patients with a diagnosis of JME were ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827290
BMC Neurology; Moon JU, Lee JY et. al.
Feb 11th, 2022 - By definition, the background EEG is normal in juvenile myoclonic epilepsy (JME) patients and not accompanied by other developmental and cognitive problems. However, some recent studies using quantitative EEG (qEEG) reported abnormal changes in th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830194
BMJ Case Reports; Mukherjee D, Bhattacharyya D et. al.
Feb 11th, 2022 - Neuronal ceroid lipofuscinosis is a rare childhood neurodegenerative disease, classified under the spectrum of progressive myoclonic epilepsy (PME). Cognitive decline, seizures including myoclonus, vision loss and ataxia are the commonly described...
Drugs 143 results
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22de2626-eef5-47a0-a254-10837e5296a3
Jun 21st, 2022 - Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older ( 1.1) Levetiracetam is indicated for adjunctive therapy for the treatment of: •Myoclonic seizures in patients 12 years of age and older wi...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dca1330-52ca-47a4-a134-ec55c9d5786d
Jun 20th, 2022 - Levetiracetam Oral Solution USP is indicated for the treatment of partial-onset seizures in patients 1 month of age and older ( 1.1) Levetiracetam Oral Solution USP is indicated for adjunctive therapy for the treatment of: Myoclonic seizures in pa...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2f5416c-631d-48cc-a6ce-f998c7217d70
Jun 8th, 2022 - Indications & Usage Section Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older (1.1) Levetiracetam is indicated for adjunctive therapy for the treatment of: Myoclonic seizures in patients 12...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90e01877-abcb-4697-a7ed-9afe5ee77050
Jun 6th, 2022 - Levetiracetam tablets USP are indicated for the treatment of partial-onset seizures in patients 1 month of age and older (1.1) Levetiracetam tablets USP are indicated for adjunctive therapy for treatment of: Partial onset seizures in patients one ...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1d71212b-ac97-4a61-8192-8e8303540019
May 31st, 2022 - Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older ( 1.1) Levetiracetam is indicated for adjunctive therapy for the treatment of: Myoclonic seizures in patients 12 years of age and older wit...
